ProfileGDS5678 / 1452945_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 62% 61% 62% 63% 68% 61% 68% 62% 61% 62% 61% 33% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7282562
GSM967853U87-EV human glioblastoma xenograft - Control 23.6978362
GSM967854U87-EV human glioblastoma xenograft - Control 33.6630561
GSM967855U87-EV human glioblastoma xenograft - Control 43.6518362
GSM967856U87-EV human glioblastoma xenograft - Control 53.7025163
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1517468
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7209461
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1710468
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6702562
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6190261
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6811362
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6167961
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7450133
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6930162